Reilly Financial Advisors buys $11,490,164 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Reilly Financial Advisors scooped up 253,051 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 255,621 shares of Abbott Laboratories which is valued at $11,490,164.Abbott Laboratories makes up approximately 2.05% of Reilly Financial Advisors’s portfolio.

Other Hedge Funds, Including , Inspirion Wealth Advisors boosted its stake in ABT in the latest quarter, The investment management firm added 11,473 additional shares and now holds a total of 227,496 shares of Abbott Laboratories which is valued at $10,225,945. Abbott Laboratories makes up approx 6.46% of Inspirion Wealth Advisors’s portfolio.Cape Ann Savings Bank boosted its stake in ABT in the latest quarter, The investment management firm added 60 additional shares and now holds a total of 21,621 shares of Abbott Laboratories which is valued at $922,136. Abbott Laboratories makes up approx 1.23% of Cape Ann Savings Bank’s portfolio.Gillespie Robinson Grimm Inc reduced its stake in ABT by selling 100 shares or 1.13% in the most recent quarter. The Hedge Fund company now holds 8,763 shares of ABT which is valued at $367,783. Abbott Laboratories makes up approx 0.06% of Gillespie Robinson Grimm Inc’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.53% at $45.02 with 76,57,947 shares getting traded on Monday. Post opening the session at $45.06, the shares hit an intraday low of $44.88 and an intraday high of $45.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *